Pasithea Therapeutics Corp (KTTA) - Net Assets
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has net assets worth $12.21 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.63 Million) and total liabilities ($1.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Pasithea Therapeutics Corp debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.21 Million |
| % of Total Assets | 89.55% |
| Annual Growth Rate | 179.75% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9196.31 |
Pasithea Therapeutics Corp - Net Assets Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Also explore Pasithea Therapeutics Corp (KTTA) total assets for the complete picture of this company's asset base.
Annual Net Assets for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual net assets of Pasithea Therapeutics Corp from 2020 to 2024. For live valuation and market cap data, see Pasithea Therapeutics Corp market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.78 Million | -36.82% |
| 2023-12-31 | $23.40 Million | -44.94% |
| 2022-12-31 | $42.50 Million | -17.35% |
| 2021-12-31 | $51.42 Million | +21204.92% |
| 2020-12-31 | $241.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pasithea Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4954179400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $139.00 | 0.00% |
| Other Comprehensive Income | $-7.17K | -0.05% |
| Other Components | $64.37 Million | 435.46% |
| Total Equity | $14.78 Million | 100.00% |
Pasithea Therapeutics Corp Competitors by Market Cap
The table below lists competitors of Pasithea Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prodigy Gold NL
AU:PRX
|
$18.84 Million |
|
Bactiquant AS
CO:BACTIQ
|
$18.84 Million |
|
Prajay Engineers Syndicate Limited
NSE:PRAENG
|
$18.85 Million |
|
Samjin LND Co. Ltd
KQ:054090
|
$18.85 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
$18.83 Million |
|
Uniserve Communications Corp
V:USS
|
$18.83 Million |
|
Catenon S.A
MC:COM
|
$18.83 Million |
|
Lipidor Ab
ST:LIPI
|
$18.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pasithea Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,398,452 to 14,782,676, a change of -8,615,776 (-36.8%).
- Net loss of 13,904,584 reduced equity.
- Dividend payments of 359,656,000 reduced retained earnings.
- Other comprehensive income decreased equity by 2,519.
- Other factors increased equity by 364,947,327.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.90 Million | -94.06% |
| Dividends Paid | $359.66 Million | -2432.96% |
| Other Comprehensive Income | $-2.52K | -0.02% |
| Other Changes | $364.95 Million | +2468.75% |
| Total Change | $- | -36.82% |
Book Value vs Market Value Analysis
This analysis compares Pasithea Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.40x to 0.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.35 | $0.84 | x |
| 2021-12-31 | $44.70 | $0.84 | x |
| 2022-12-31 | $33.67 | $0.84 | x |
| 2023-12-31 | $19.08 | $0.84 | x |
| 2024-12-31 | $13.49 | $0.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pasithea Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-94.06%) is below the historical average (-44.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -25.47% | 0.00% | 0.00x | 1.03x | $-85.61K |
| 2021 | -4.23% | -14430.49% | 0.00x | 1.04x | $-7.32 Million |
| 2022 | -32.79% | -2864.29% | 0.01x | 1.06x | $-18.19 Million |
| 2023 | -68.22% | -3280.52% | 0.02x | 1.12x | $-18.30 Million |
| 2024 | -94.06% | 0.00% | 0.00x | 1.09x | $-15.38 Million |
Industry Comparison
This section compares Pasithea Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pasithea Therapeutics Corp (KTTA) | $12.21 Million | -25.47% | 0.12x | $18.84 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more